Author:
Leehey David J.,Rahman Mohamed A.,Borys Ewa,Picken Maria M.,Clise Christina E.
Subject
Nephrology,Internal Medicine
Reference15 articles.
1. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy;Perkovic;N Engl J Med,2019
2. Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials;Kristensen;Lancet Diabetes Endocrinol,2019
3. Advera Health Analytics, Inc. (2020) “FAERS Adverse Event, Acute Kidney Injury, Glucagon-like peptide-1 (GLP-1) Analogues Classification Comparison Report.” Evidex. https://www.adverahealth.com/explorer/#/druggroup/drugclass/A10BJ/pivot/ROR?event_id=10069339. Accessed April 24, 2020.
4. A method for estimating the probability of adverse drug reactions;Naranjo;Clin Pharmacol Ther,1981
5. Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): a randomised, open-label, phase 3b trial;Pratley;Lancet Diabetes Endocrinol,2018
Cited by
26 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献